Format

Send to

Choose Destination
Int J Mol Sci. 2015 Aug 3;16(8):17812-25. doi: 10.3390/ijms160817812.

Composition, Cytotoxic and Antimicrobial Activities of Satureja intermedia C.A.Mey Essential Oil.

Author information

1
Zabol Medicinal Plants Research Center, Zabol University of Medical Sciences, Zabol 61615-585, Iran. javad.sharifirad@gmail.com.
2
Department of Pharmacognosy, Faculty of Pharmacy, Zabol University of Medical Sciences, Zabol 61615-585, Iran. javad.sharifirad@gmail.com.
3
Department of Medical Parasitology, Zabol University of Medical Sciences, Zabol 61663-335, Iran. mehdi_sharifirad@yahoo.com.
4
Pediatric Infections Research Center, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran 15468-15514, Iran. m.hoseinialfatemi@gmail.com.
5
Department of Agricultural and Environmental Sciences, Milan State University, via G. Celoria 2, Milan 20133, Italy. marcello.iriti@unimi.it.
6
Department of Range and Watershed Management, Faculty of Natural Resources, University of Zabol, Zabol 98615-538, Iran. majid.sharifirad@gmail.com.
7
Department of Chemistry, Faculty of Science, University of Zabol, Zabol 98615-538, Iran. marzieh.sharifirad@gmail.com.

Abstract

In this study, the essential oil (EO) constituents from the aerial parts of Satureja intermedia C.A.Mey were detected by GC and GC/MS. The antimicrobial activity of EO on oral pathogens and its cytotoxicity to human cancer cells were determined by the microbroth dilution method and the crystal violet staining method, respectively. Thirty-nine compounds were identified and the main EO constituents were γ-terpinene (37.1%), thymol (30.2%), p-cymene (16.2%), limonene (3.9%), α-terpinene (3.3%), myrcene (2.5%), germacrene B (1.4%), elemicine (1.1%) and carvacrol (0.5%). The S. intermedia EO showed a concentration-dependent decrease in viability of Hep-G2 (hepatocellular carcinoma) and MCF-7 (breast adenocarcinoma) human cancer cell lines (p < 0.05). Antimicrobial screening of S. intermedia EO demonstrated slight antibacterial and antifungal activities against Streptococcus mutants, S. salivarius, Enterococcus faecalis, Staphylococcus aureus, Candida albicans and C. glabrata. Further preclinical studies are needed to assess the efficacy and safety of S. intermedia EO as a new promising anticancer agent.

KEYWORDS:

C/MS; breast adenocarcinoma; hepatocellular carcinoma; human cancer cells; oral pathogens

PMID:
26247936
PMCID:
PMC4581223
DOI:
10.3390/ijms160817812
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center